BioSpace News Archive

Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, announced positive top-line efficacy data for NUZYRA® as post-exposure prophylaxis in a non-human primate model of inhalational anthrax.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees stock options to purchase an aggregate of 16,050 shares, and restricted stock units covering an aggregate of 11,300 shares, of BioCryst common stock.

Axsome Therapeutics, Inc. announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, at 9:20 a.m. Eastern Time at the Fontainebleau in Miami Beach, Florida.

ADMA Biologics, Inc. announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 6, 2024, at 11:35 a.m. ET.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced its plans to transition its corporate headquarters to Frederick, Maryland.

Praxis Precision Medicines, Inc. provided a corporate update and reported financial results for the fourth quarter and full-year 2023.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, announced positive preclinical imaging data of a therapeutic radioisotope bound to its proprietary uPAR targeting agent MNPR-101.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.

Tiziana Life Sciences Ltd., a biotechnology company developing breakthrough neuro-immunomodulation therapies, announced that Dr. Howard Weiner will present positive data of intranasal anti-CD3 monoclonal antibody in models of Alzheimer’s and Parkinson’s disease at AD/PD, March 5-9, 2024.

Chemomab Therapeutics Ltd., a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, announced that CEO Dr. Adi Mor will deliver a corporate presentation and participate in investor meetings at the Leerink Partners Global Biopharma Conference, March 11-13, 2024 in Miami, Florida.